Zi Jun “Emma” Wang was employed at Beam Therapeutics from March 2021 to January 2022, after which Beam alleges she used internal data to launch YolTech and related patent applications.
After Wang left, YolTech, led by CEO Yuxuan “Jensen” Wu, signed a licensing deal with Serapha Bio. The agreement handed over rights to an experimental therapy for alpha-1 antitrypsin deficiency (AATD). This rare disease is a hot spot for gene editing firms. The money behind the deal is still secret. But Serapha’s plans are public. The company wants to go public through a reverse merger and speed up work on the therapy. It has $230 million in backing from RA Capital Management and RTW Investments.
Beam’s own AATD drug, BEAM-302, uses its base editing platform. This technology makes single-letter changes in DNA. According to a Reuters company profile, Beam’s rare disease programs rely on this base editing method. Early trial results show BEAM-302 can restore a key protective protein in patients. Beam is now enrolling more people in a new study. If results stay strong, the company hopes for fast-track U.S. approval. In court, Beam claims Serapha’s drug, “SERP-01,” targets the same genetic mutation and uses the same DNA change as BEAM-302. Beam says this is proof its technology was taken.
The dispute centers on therapies for alpha-1 antitrypsin deficiency (AATD), a rare liver and lung disease. This area became the subject of a licensing deal between YolTech and Serapha, with both companies now facing Beam’s legal challenge.
This case is not just a private feud. It tests the limits of intellectual property in gene editing. Both BEAM-302 and SERP-01 go after the same rare disease mutation with similar editing tools. The outcome could shake the biotech sector. Proprietary editing platforms are now big business. Companies risk losing their edge when staff and know-how move across borders. Beam’s lawsuit sends a message. Trade secrets are now a battleground. The old days of easy tech transfer are over.
YolTech says it will fight Beam’s claims, according to The Boston Globe. So far, there are no court rulings, injunctions, or verdicts on the main dispute.
